Toward identifying new strategies to target gastric cancer stem-like cells (CSCs), we evaluated the function of the tumour suppressor CDK5 regulatory subunit-associated protein 3 (CDK5RAP3) in gastric CSC maintenance.
We examined the expression of CDK5RAP3 and CD44 in gastric cancer patients. The function and mechanisms of CDK5RAP3 were checked in human and mouse gastric cancer cell lines and in mouse xenograft.
We show that CDK5RAP3 is weakly expressed in gastric CSCs and is negatively correlated with the gastric CSC marker CD44. CDK5RAP3 overexpression decreased expression of CSC markers, spheroid formation, invasion and migration, and reversed chemoresistance in gastric CSCs in vitro and vivo. CDK5RAP3 expression was found to be regulated by extracellular-related kinase (ERK) signalling. ERK inhibitors decreased spheroid formation, migration and invasion, and the expression of epithelial-to-mesenchymal transition (EMT)-related proteins in both GA cells and organoids derived from a genetically engineered mouse model of GA. Finally, CDK5RAP3 expression was associated with reduced lymph-node metastasis and better prognosis, even in the presence of high expression of the EMT transcription factor Snail, among patients with CD44-positive GA.
Our results demonstrate that CDK5RAP3 is suppressed by ERK signalling and negatively regulates the self-renewal and EMT of gastric CSCs.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J. & Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018).
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A. & Fleig, W. E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24, 2903–2909 (2006).
Easwaran, H., Tsai, H. C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell. 54, 716–727 (2014).
Pan, Y., Ma, S., Cao, K., Zhou, S., Zhao, A., Li, M. et al. Therapeutic approaches targeting cancer stem cells. J. Cancer Res. Ther. 14, 1469–1475 (2018).
Nguyen, P. H., Giraud, J., Chambonnier, L., Dubus, P., Wittkop, L., Belleannée, G. et al. Characterization of biomarkers of tumorigenic and chemoresistant cancer stem cells in human gastric carcinoma. Clin. Cancer Res. 23, 1586–1597 (2017).
Bekaii‐Saab, T. & El‐Rayes, B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer 123, 1303–1312 (2017).
Wang, L., Zuo, X., Xie, K. & Wei, D. in Cancer Stem Cells (Springer, 2018) pp 31–42.
Takaishi, S., Okumura, T., Tu, S., Wang, S. S., Shibata, W., Vigneshwaran, R. et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006–CD1020 (2009).
Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611–629 (2017).
Jiang, H., Wu, J., He, C., Yang, W. & Li, H. Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation. Cell Res. 19, 458–468 (2009).
Wang, J., An, H., Mayo, M. W., Baldwin, A. S. & Yarbrough, W. G. LZAP, a putative tumor suppressor, selectively inhibits NF-κB. Cancer Cell. 12, 239–251 (2007).
Wang, J. B., Wang, Z. W., Li, Y., Huang, C. Q., Zheng, C. H., Li, P. et al. CDK5RAP3 acts as a tumor suppressor in gastric cancer through inhibition of β-catenin signaling. Cancer Lett. 385, 188–197 (2017).
Zheng, C. H., Wang, J. B., Lin, M. Q., Zhang, P. Y., Liu, L. C., Lin, J. X. et al. CDK5RAP3 suppresses Wnt/β-catenin signaling by inhibiting AKT phosphorylation in gastric cancer. J. Exp. Clin. Cancer Res. 37, 59 (2018).
Cho, S. J., Kook, M. C., Lee, J. H., Shin, J. Y., Park, J., Bae, Y. K. et al. Peroxisome proliferator‐activated receptor γ upregulates galectin‐9 and predicts prognosis in intestinal‐type gastric cancer. Int. J. Cancer 136, 810–820 (2015).
Yoon, C., Cho, S. J., Aksoy, B. A., Park, D. J., Schultz, N., Ryeom, S. W. et al. Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells. Clin. Cancer Res. 22, 971–983 (2016).
Masters, J., Twentyman, P., Daley, R., Davis, J., Doyle, A., Dyer, S. et al. UKCCCR guidelines for the use of cell lines in cancer research. Br. J. Cancer 82, 1495–1509 (2000).
Cho, S. J., Yoon, C., Lee, J. H., Chang, K. K., Lin, J. X., Kim, Y. H. et al. KMT2C mutations in diffuse type gastric adenocarcinoma promote epithelial-to-mesenchymal transition. Clin. Cancer Res. 1679, 2017 (2018).
Yoon, C., Park, D. J., Schmidt, B., Thomas, N. J., Lee, H. J., Kim, T. S. et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin. Cancer Res. 20, 3974–3988 (2014).
Bisson, I. & Prowse, D. M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 19, 683–697 (2009).
Yoon, S. S., Eto, H., Lin, C. M., Nakamura, H., Pawlik, T. M., Song, S. U. et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res. 59, 6251–6256 (1999).
Till, J. E., Yoon, C., Kim, B. J., Roby, K., Addai, P., Jonokuchi, E. et al. Oncogenic KRAS and p53 loss drive gastric tumorigenesis in mice that can be attenuated by E-cadherin expression. Cancer Res. 77, 5349–5359 (2017).
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
Hong, D., Fritz, A. J., Zaidi, S. K., van Wijnen, A. J., Nickerson, J. A., Imbalzano, A. N. et al. Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. J. Cell Physiol. 233, 9136–9144 (2018).
McCracken, K. W., Catá., E. M., Crawford, C. M., Sinagoga, K. L., Schumacher, M., Rockich, B. E. et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516, 400–404 (2014).
Mak, G. W. Y., Chan, M. M. L., Leong, V. Y. L., Lee, J. M. F., Yau, T. O., Ng, I. O. L. et al. Overexpression of a novel activator of PAK4, the CDK5 kinase associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res. 71, 2949–2958 (2011).
Wamsley, J., Gary, C., Biktasova, A., Hajek, M., Bellinger, G., Virk, R. et al. Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner. Oncogenesis 6, e314 (2017).
Maehara, O., Suda, G., Natsuizaka, M., Ohnishi, S., Komatsu, Y., Sato, F. et al. Fibroblast growth factor-2–mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis 38, 1073–1083 (2017).
Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128–134 (2018).
Beck, B., Lapouge, G., Rorive, S., Drogat, B., Desaedelaere, K., Delafaille, S. et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 16, 67–79 (2015).
Guo, W., Keckesova, Z., Donaher, J. L., Shibue, T., Tischler, V., Reinhardt, F. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015–1028 (2012).
Ye, X., Tam, W. L., Shibue, T., Kaygusuz, Y., Reinhardt, F., Eaton, E. N. et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256–260 (2015).
We would like to thank Dr. Hassan Ashktorab and Dr. Duane T. Smoot for providing the HFE-145 cell line. We also thank MSKCC senior editor Jessica Moore for reviewing this manuscript.
Ethics approval and consent to participate
This study was approved by the institutional review board of the Memorial Sloan Kettering Cancer Center (MSKCC) and Fujian Medical University Union Hospital. All animal procedures were done accordingly with the MSKCC Institutional Animal Care and Use Committee. The use of human tissue samples and clinical data was approved by the ethics committee of FMUUH. The requirement of informed consent from the patients was waived because of the retrospective design of this study, and patients’ information was protected. All procedures performed in the study involving human participants were in accordance with the Declaration of Helsinki.
All data and material presented in this article and in the supplementary information are available upon request from the corresponding authors.
The authors declare no competing interests.
This study was funded by National Natural Science Foundation of China (No. 81871899); Construction Project of Fujian Province Minimally Invasive Medical Center, China (No. 171); NIH grants R01 CA158301 (SSY) and P30 CA008748; Project supported by the Science Foundation of the Fujian Province, China (No. 2018J01307); Joint Funds for the Innovation of Scientific and Technological, Fujian Province (No. 2018Y9008). The general project of sailing fund of Fujian Medical University (2017XQ1026).
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lin, Jx., Yoon, C., Li, P. et al. CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer. Br J Cancer 123, 1131–1144 (2020). https://doi.org/10.1038/s41416-020-0963-y